ADAPT

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024

“We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.

Key Points: 
  • “We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.
  • These positive data from the ADHERE study have been submitted to the FDA for potential approval of VYVGART Hytrulo in CIDP with a PDUFA target action date of June 21, 2024.
  • Achievement of MSE enables significant quality of life improvements: ADAPT/ADAPT+ demonstrate that >40% of patients achieve minimal symptom expression (MSE) across both studies.
  • Patients achieving MSE experience quality of life outcomes comparable to healthy populations, suggesting MSE could be a primary goal of gMG treatment.

UCSF Rosenman Institute Awards 2023 ADAPT to Innovative Healthcare Startups Neura Health and ThriveLink

Retrieved on: 
Tuesday, February 27, 2024

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- The UCSF Rosenman Institute announces Neura Health and ThriveLink as the recipients of the 2023 UCSF Rosenman ADAPT program (ADAPT) awards. This marks a significant achievement in healthcare innovation, accelerating the development of telehealth and AI-driven healthcare solutions that address healthcare delivery and equity.

Key Points: 
  • SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- The UCSF Rosenman Institute announces Neura Health and ThriveLink as the recipients of the 2023 UCSF Rosenman ADAPT program (ADAPT) awards.
  • This marks a significant achievement in healthcare innovation, accelerating the development of telehealth and AI-driven healthcare solutions that address healthcare delivery and equity.
  • Neura Health and ThriveLink will each receive $100,000 in non-dilutive funding and have the unique opportunity to collaborate with ADAPT program partners.
  • Christine Winoto, Executive Director of the UCSF Rosenman Institute, underscores the impact of the ADAPT program: "This initiative is not just an award; it's a catalyst bringing together agile healthcare startups and established companies.

Red Door Capital Partners increases their ownership in Adapt Ideations Global PTE LTD ("Adapt"), a technology company in global logistics, data intelligence and supply chain management.

Retrieved on: 
Tuesday, February 27, 2024

Adapt Ideations specializes in providing innovative supply chain and logistics solutions to the Cold Chain and a variety of other industry sectors.

Key Points: 
  • Adapt Ideations specializes in providing innovative supply chain and logistics solutions to the Cold Chain and a variety of other industry sectors.
  • They offer a wide range of IoT ("Internet of Things") enabled asset tracking and monitoring solutions to enhance supply chain visibility and ensure adherence to compliance and regulations.
  • We look forward to a continued partnership with Red Door, Onset and all out consultants to achieve this goal".
  • "The Restructure Round demonstrates our ability to quickly respond and adapt to market changes without losing momentum", asserts Co-Founder, Director Anirban Gupta.

Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH

Retrieved on: 
Friday, January 5, 2024

The data were presented at NASH-TAG 2024 (Jan. 4-6, 2024) in Park City, Utah.

Key Points: 
  • The data were presented at NASH-TAG 2024 (Jan. 4-6, 2024) in Park City, Utah.
  • “This low immunogenicity distinguishes BOS-580 from other FGF21 analogues currently in development.”
    Another analysis of data from Boston Pharmaceuticals’ Phase 2a trial demonstrated the impact of BOS-580 treatment on several non-invasive indicators of fibrosis based on markers of liver injury and fibrosis in MASH patients.
  • “Our latest data highlight that BOS-580 has great potential to become a backbone in the treatment of patients suffering from MASH.
  • We believe BOS-580 may offer a compelling and convenient treatment option for people living with MASH,” said Juan Carlos Lopez-Talavera, M.D., Ph.D., CMO of Boston Pharmaceuticals.

Seagate Takes Its High-Performing Multi-Petabyte Capacity Block Storage System to New Heights Reaching 2.5 PB

Retrieved on: 
Tuesday, November 14, 2023

Seagate Technology Holdings plc (NASDAQ: STX), a world leader in mass data storage infrastructure solutions, today announced the latest Seagate Exos® CORVAULT™ 4U106 mass data storage system.

Key Points: 
  • Seagate Technology Holdings plc (NASDAQ: STX), a world leader in mass data storage infrastructure solutions, today announced the latest Seagate Exos® CORVAULT™ 4U106 mass data storage system.
  • Offering capacity of 2.5PB, the high-performing multi-petabyte block storage system offers higher rack density, extended lifecycles, and less power per petabyte, lowering total cost of ownership (TCO).
  • The Seagate Exos CORVAULT 4U106 features Seagate’s high capacity Exos® hard drives, which, combined with self-healing technology, create the most efficient petabyte storage building block for scale-out data center architecture, reducing storage networking resources up to 50% and improving total rack power efficiency up to 30%.
  • Both capacities in the new configurations can be ordered from storage resellers worldwide in November with product availability at the end of December.

BAE Systems unveils ADAPT virtual environment to advance mission outcomes

Retrieved on: 
Tuesday, November 28, 2023

ORLANDO, Fla. and MCLEAN, Va., Nov. 28, 2023 /PRNewswire/ -- BAE Systems unveiled its advanced digital analysis and prototyping testbed, also known as ADAPT, at the annual I/ITSEC in Orlando, Florida.

Key Points: 
  • ORLANDO, Fla. and MCLEAN, Va., Nov. 28, 2023 /PRNewswire/ -- BAE Systems unveiled its advanced digital analysis and prototyping testbed, also known as ADAPT, at the annual I/ITSEC in Orlando, Florida.
  • ADAPT is an integrated virtual environment designed to provide comprehensive analysis across multiple warfighting domains, improving the ability of decision-makers to predict, adapt, and win in contested, evolving environments.
  • In addition to mission and information analysis, ADAPT provides system of systems analysis through the integration of model-based system engineering in which it can assess, trade, and optimize architecture and requirements in a digital environment.
  • For more than 30 years, BAE Systems has supported the U.S. government with enterprise IT, engineering, and system integration services, advancing technologies and keeping in step with its evolving mission requirements.

CORRECTION: National Youth Prevention Summit Highlights Colorado Campaign to Protect Teens from Fentanyl

Retrieved on: 
Friday, November 3, 2023

Denver, Colo., Nov. 03, 2023 (GLOBE NEWSWIRE) -- A national youth prevention summit organized by the National High Intensity Drug Trafficking Areas (HIDTA) Program in October highlighted Colorado’s new youth fentanyl prevention campaign, which uses the power of positive social norms to limit pill misuse by adolescents.

Key Points: 
  • Denver, Colo., Nov. 03, 2023 (GLOBE NEWSWIRE) -- A national youth prevention summit organized by the National High Intensity Drug Trafficking Areas (HIDTA) Program in October highlighted Colorado’s new youth fentanyl prevention campaign, which uses the power of positive social norms to limit pill misuse by adolescents.
  • That included surveys of youth and parents, focus groups, and engagement with youth organizations like Rise Above Colorado, which served as a partner in the campaign.
  • It highlights, among other statistics, that 87% of Colorado teens would act to protect their friends from pills that could contain fentanyl.
  • Recordings of the full summit, including the presentation on the Colorado campaign and related materials, can be accessed at ADAPT’s website .

National Youth Prevention Summit Highlights Colorado Campaign to Protect Teens from Fentanyl

Retrieved on: 
Friday, November 3, 2023

Denver, Colorado, Nov. 02, 2023 (GLOBE NEWSWIRE) -- A national youth prevention summit organized by the National High Intensity Drug Trafficking Areas (HIDTA) Program in October highlighted Colorado’s new youth fentanyl prevention campaign, which uses the power of positive social norms to limit pill misuse by adolescents.

Key Points: 
  • Denver, Colorado, Nov. 02, 2023 (GLOBE NEWSWIRE) -- A national youth prevention summit organized by the National High Intensity Drug Trafficking Areas (HIDTA) Program in October highlighted Colorado’s new youth fentanyl prevention campaign, which uses the power of positive social norms to limit pill misuse by adolescents.
  • That included surveys of youth and parents, focus groups, and engagement with youth organizations like Rise Above Colorado, which served as a partner in the campaign.
  • It highlights, among other statistics, that 87% of Colorado teens would act to protect their friends from pills that could contain fentanyl.
  • Recordings of the full summit, including the presentation on the Colorado campaign and related materials, can be accessed at ADAPT’s website .

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 1, 2023

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates.

Key Points: 
  • ET
    CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates.
  • Leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity, Cerevel is advancing its broad and diverse pipeline of novel neuroscience product candidates.
  • Cerevel is conducting the REALIZE trial, a Phase 2 proof-of-concept trial in focal epilepsy, and a corresponding open-label safety extension trial.
  • ET to discuss its third quarter 2023 financial results and key pipeline and business updates.

Tivoli Lighting Introduces Quick Ship Program

Retrieved on: 
Tuesday, October 3, 2023

With more than 50 years of innovation and linear lighting leadership, Tivoli Lighting announces its Tivoli Quick Ship Program that guarantees its lighting products will be received within seven (7) days in North America.

Key Points: 
  • With more than 50 years of innovation and linear lighting leadership, Tivoli Lighting announces its Tivoli Quick Ship Program that guarantees its lighting products will be received within seven (7) days in North America.
  • The Quick Ship Program was developed for fast-moving construction projects to ensure that schedules are met for a wide range of architectural lighting products without sacrificing quality and performance.
  • All Quick Ship purchase orders must be clearly titled “Quick Ship” at submission.
  • For more information about the Tivoli Quick Ship Program, contact Tivoli at 714-957-6101 or visit https://tivolilighting.com/tivoli-quick-ship-program .